8,10,10-Trimethyl-6-azatricyclo[6.3.1.01,6]dodecan-5-one | 607733-79-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 8,10,10-Trimethyl-6-azatricyclo[6.3.1.01,6]dodecan-5-one
• CAS: 607733-79-9
• 化学式: C₁₄H₂₃NO
• 分子量: 221.343
• InChiKey: DIQUKSUMOXYIBN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  16
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.93
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
  申请人：——

  公开号：US20040087658A1

  公开（公告）日：2004-05-06

  The invention relates to a novel drug combination therapy useful in the treatment of dementia comprising administering an 1-aminocyclohexane derivative such as memantine or neramexane and an acetylcholinesterase inhibitor (AChEI) such as galantamine, tacrine, donepezil, or rivastigmine.

  该发明涉及一种新型药物组合疗法，可用于治疗痴呆，包括给予一种1-氨基环己烷衍生物，如美万特或奈拉美喜，以及一种乙酰胆碱酯酶抑制剂（AChEI），如加兰他明、他克林、多奈哌齐或利伐替明。
• Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexane NMDA, 5HT3 and neuronal nicotinic receptor antagonists
  申请人：Parsons Graham Raphael Christopher

  公开号：US20060019982A1

  公开（公告）日：2006-01-26

  Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexanes which are systemically-active as NMDA, 5HT 3 , and nicotinic receptor antagonists, pharmaceutical compositions comprising the same, method of preparation thereof, and method of treating CNS disorders which involve disturbances of glutamatergic, serotoninergic, and nicotinic transmission, treating immunomodulatory disorders, and antimalaria, antitrypanosomal, anti-Borna virus, anti-HSV and anti-Hepatitis C virus activity.

  氨基环己烷的氮杂双环、氮杂三环和氮杂螺环衍生物，作为NMDA、5HT3和尼古丁受体拮抗剂具有系统活性，包括这些衍生物的制药组合物，其制备方法，以及用于治疗涉及谷氨酸能、血清素能和尼古丁能传递干扰的中枢神经系统疾病、治疗免疫调节性疾病、以及抗疟疾、抗锥虫病、抗Bornavirus、抗HSV和抗丙型肝炎病毒活性的方法。
• Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists
  申请人：MERZ PHARMA GMBH & CO. KGAA

  公开号：US20040034055A1

  公开（公告）日：2004-02-19

  Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexanes which are systemically-active as NMDA, 5HT 3 , and nicotinic receptor antagonists, pharmaceutical compositions comprising the same, method of preparation thereof, and method of treating CNS disorders which involve disturbances of glutamatergic, serotoninergic, and nicotinic transmission, treating immunomodulatory disorders, and antimalaria, antitrypanosomal, anti-Borna virus, anti-HSV and anti-Hepatitis C virus activity.

  氨基环己烷的氮杂环、三氮杂环和氮杂螺环衍生物在NMDA、5HT3和尼古丁受体拮抗剂方面具有系统活性，包括这些衍生物的药物组合物、其制备方法，以及用于治疗涉及谷氨酸能、血清素能和尼古丁能传递干扰的中枢神经系统紊乱、治疗免疫调节紊乱以及抗疟疾、抗锥虫病、抗Bornavirus、抗HSV和抗丙型肝炎病毒活性的方法。
• Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase and inhibitors
  申请人：Moebius Hans-Joerg

  公开号：US20090124659A1

  公开（公告）日：2009-05-14

  The invention relates to a novel drug combination therapy useful in the treatment of dementia comprising administering an 1-aminocyclohexane derivative such as memantine or neramexane and an acetylcholinesterase inhibitor (AChEI) such as galantamine, tacrine, donepezil, or rivastigmine.

  本发明涉及一种新型药物组合疗法，用于治疗痴呆症，包括给予1-氨基环己烷衍生物，如美金刚烷或内拉美昔，并且给予乙酰胆碱酯酶抑制剂（AChEI），如加兰他敏、他克林、多奈哌齐或利他林。
• COMBINATION THERAPY USING 1-AMINOCYCLOHEXANE DERIVATIVES AND ACETYLCHOLINESTERASE INHIBITORS
  申请人：MERZ PHARMA GmbH & CO. KGaA

  公开号：US20140371260A1

  公开（公告）日：2014-12-18

  The invention relates to a novel drug combination therapy useful in the treatment of dementia comprising administering an 1-aminocyclohexane derivative such as memantine or neramexane and an acetylcholinesterase inhibitor (AChEI) such as galantamine, tacrine, donepezil, or rivastigmine.

  本发明涉及一种新型药物组合疗法，用于治疗痴呆症，包括给予1-氨基环己烷衍生物，如美金刚烷或尼拉美昔，以及乙酰胆碱酯酶抑制剂（AChEI），如加兰他敏、他克林、多奈哌齐或利伐他汀。